Metsera expects its cash will last into 2027. Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Cystic fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint bookrunners for the offering.

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last ...